Fund Details
Overview
Investment portfolio
35rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Signadori Bio | May 2026Participated | $13 MSeed | |
Storm Therapeutics | Apr 2026Participated | $56 MSeries C | |
Crossbow Therapeutics | Mar 2026Led | $77 MSeries B | |
EpiBiologics | Jan 2026Participated | $107 MSeries B | |
Normunity | Jan 2025Participated | $75 MSeries B | |
Light Horse Therapeutics | Jan 2025Participated | $62 MSeries A | |
Halda Therapeutics | Aug 2024Participated | $126 MSeries B | |
Libero Thera | Aug 2024Participated | $1 MOther Equity | |
Theolytics | Apr 2024Participated | $24 MOther Equity | |
EpiBiologics | Jul 2023Participated | $23 MSeries A | |
Anavo Therapeutics | May 2023Participated | $9 MSeed | |
Cellvie | Feb 2023Led | $6 MOther Equity | |
Signadori Bio | May 2026Participated | $13 MSeed | |
Storm Therapeutics | Apr 2026Participated | $56 MSeries C | |
Crossbow Therapeutics | Mar 2026Led | $77 MSeries B | |
EpiBiologics | Jan 2026Participated | $107 MSeries B | |
Normunity | Jan 2025Participated | $75 MSeries B | |
Light Horse Therapeutics | Jan 2025Participated | $62 MSeries A | |
Halda Therapeutics | Aug 2024Participated | $126 MSeries B | |
Libero Thera | Aug 2024Participated | $1 MOther Equity | |
Theolytics | Apr 2024Participated | $24 MOther Equity | |
EpiBiologics | Jul 2023Participated | $23 MSeries A | |
Anavo Therapeutics | May 2023Participated | $9 MSeed | |
Cellvie | Feb 2023Led | $6 MOther Equity |
35 Items
35
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 3 |
| Series A | 4 | 8 |
| Series B | 2 | 9 |
| Series C+ | 0 | 5 |
| Other Equity | 2 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '16 | 1 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 1 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 1 |
| Dec '17 | 0 |
| Jan '18 | 1 |
| Feb '18 | 2 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 2 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 1 |
| Jun '19 | 1 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 1 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 1 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 2 |
| Feb '21 | 1 |
| Mar '21 | 0 |
| Apr '21 | 1 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 1 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 2 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 1 |
| Nov '22 | 1 |
| Dec '22 | 1 |
| Jan '23 | 0 |
| Feb '23 | 1 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 1 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 1 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 2 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 2 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 1 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 1 |
| May '26 | 1 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 35 |
| Manufacturing | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 4 |
| $10M-$25M | 7 |
| $25M-$50M | 4 |
| $50M-$100M | 16 |
| $100M-$250M | 3 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 25 |
| Europe | 9 |
| Japan | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| M Ventures | 6 |
| MPM Capital | 6 |
| Pfizer Ventures | 6 |
| Alexandria Venture Investments | 5 |
| BVF Partners | 4 |
| Canaan Partners | 4 |
| 8VC | 3 |
| Arkin Bio Ventures | 3 |
| Bristol Myers Squibb | 3 |
| Foresite Capital | 3 |
| Google Ventures | 3 |
| HBM Healthcare Investments | 3 |
| IP Group | 3 |
| Longwood Fund | 3 |
| Mission BioCapital | 3 |
| NS Investment | 3 |
| OrbiMed | 3 |
| Polaris Partners | 3 |
| The Column Group | 3 |
| UTokyo Innovation Platform | 3 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 8 | 23% |
| Participating | 27 | 77% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 3 | 38% |
| Co-led | 5 | 63% |
Team
Sakae Asanuma
Founding President & CEO